title: Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer.
abstract: Breast cancer is the most common type of cancer among females and the 5th most common cause of cancer death. About 5-10% of breast cancers occur due to gene mutations inherited from mother or father. The molecular basis of breast cancer has been extensively investigated, making gene therapy a potential new therapeutic alternative. Mutation compensation, molecular chemotherapy, proapoptotic gene therapy, antiangiogenic gene therapy, genetic immunopotentiation and genetic modulation of resistance/sensitivity are the main gene therapies used. The combination of gene therapy with chemotherapy or radiation is being investigated in ongoing trials. The purpose of this review was to make a synopsis of the currently existing target therapies in breast cancer.
authors.affiliation: 3rd Department of Obstetrics and Gynecology, "Attikon" University Hospital, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Grammatikakis
authors.forename: S
authors.initials: S
authors.lastname: Zervoudis
authors.forename: D
authors.initials: D
authors.lastname: Kassanos
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D009154:Mutation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents